Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5

NACompletedINTERVENTIONAL
Enrollment

2,871

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Carcinoma, HepatocellularLiver Neoplasms
Interventions
BEHAVIORAL

Outreach with patient education and patient navigation services

"* Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Parkland Health and Hospital System

OTHER

collaborator

Michael E. DeBakey VA Medical Center

FED

lead

University of Texas Southwestern Medical Center

OTHER

NCT02582918 - Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5 | Biotech Hunter | Biotech Hunter